SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

FIG is trending following strong quarterly results and an optimistic outlook, with its new AI integrations, including an Anthropic partnership, fueling bullish sentiment that the company is adapting to evolving industry dynamics. The community is buzzing about potential for a short squeeze and a rebound from the broader software sector's recent challenges.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space is buzzing as executives are set to ring the NYSE Opening Bell, an event that has the community speculating on a significant short squeeze given the stock's tight float and its positioning within the rapidly evolving hypersonic technology sector.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing intense scrutiny following its latest earnings, which revealed strong revenue growth and expanding user base in the US, but also an unexpected net loss driven by increased credit loss provisions. The community is sharply divided, debating whether the fintech's pivot to a broader digital banking model presents a compelling "buy the dip" opportunity or signals deeper challenges within the BNPL sector amid ongoing class-action lawsuits and broader market caution towards fintech IPOs.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is a major talking point following its Q4 earnings beat and a significant share buyback announcement, though many in the community are debating if its current high valuation is justified given conservative future guidance and competition from Amazon.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after competitor Corcept Therapeutics received an FDA rejection for its Cushing's syndrome drug, which many believe significantly expands the market opportunity for Xeris's Recorlev. This development, alongside Xeris's pre-announced strong Q4 revenue and path to profitability, is driving community optimism about its undervalued position and future growth.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co. is trending after an earnings report showed revenue beats and raised guidance, despite a decline in profits, leading to a fierce debate among investors about the stock's valuation and the agricultural cycle's true bottom. Bulls celebrate the strength in construction and small ag, while bears point to falling net income, high P/E ratios, and concerns over channel stuffing.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

MPT's strong Q4 earnings, beating revenue and EPS estimates and reaffirming 2026 guidance, are driving bullish sentiment and sparking calls for a significant turnaround and potential short squeeze among the community, which believes many shorts are now trapped.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as its recent European approval for ANKTIVA and a new distribution partnership ignite intense community speculation about a looming short and gamma squeeze, further fueled by a fresh FDA submission for an additional bladder cancer indication.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana (CVNA) is trending as the community scrutinizes its recent earnings, which show reliance on a one-time tax benefit and alleged deceptive accounting practices, particularly regarding related-party loan sales. These concerns are amplified by a new Gotham report and the CEO's perceived evasiveness in recent interviews, leading many to label the business model as a "scam."

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community highly anticipates the BLA resubmission for its Duchenne Muscular Dystrophy therapy by month-end, fueled by robust Phase 3 data and increasing institutional interest, despite concerns about broader FDA regulatory consistency.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ansys, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - ANSS

Ansys, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - ANSS Ansys, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your...

ANSS Investors Have Opportunity to Join Ansys, Inc. Fraud Investigation with the Schall Law Firm

ANSS Investors Have Opportunity to Join Ansys, Inc. Fraud Investigation with the Schall Law Firm ANSS Investors Have Opportunity to Join Ansys, Inc. Fraud Investigation with the Schall Law Firm PR...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ansys, Inc. (Ansys or the Company) (NASDAQ: ANSS) for...

The Trade Desk Stock Climbs Higher on S&P 500 Debut as ANSYS Drops Out

TTD jumps 6.6% as it joins the S&P 500. The company expects CTV growth, Kokai demand and global ad trends to fuel momentum.

Ansys Acquisition by Synopsys Clears Regulatory Hurdles Worldwide

ANSS moves closer to merging with Synopsys as final global approvals secure $35B deal set to close July 17.

Ansys (ANSS) Moves 3.0% Higher: Will This Strength Last?

Ansys (ANSS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

China's antitrust authority has greenlit Synopsys Inc.(SNPS)'s $35 billion acquisition of engineering software firm Ansys Inc. (ANSS), clearing the final international hurdle for the deal between two key players in&nbsp;the electronic design automation (EDA)&nbsp;industry.According to a Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/china/china-grants-conditional-approval-synopsys-acquire-ansys-2025-07-14/">report</a>, the conditional approval from the State Administration for Market Regulation (SAMR) came just days ahead of the deal’s July 15 closure deadline.&nbsp;Following the news,&nbsp;<a href="https://stocktwits.com/symbol/SNPS">Synopsys stock</a> traded 3.3% higher in Monday’s premarket session.While regulatory bodies in other key global markets had already approved the transaction, doubts lingered over whether Chinese authorities would delay the deal due to ongoing political and trade friction.&nbsp;Investor anxiety grew after the United States imposed limits on the export of specific semiconductor design technologies to China, prompting speculation that Beijing might respond with its countermeasures.Synopsys had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/synopsys-restarts-partial-services-in-china-amid-us-export-curbs/chlXDS8Rb6s">suspended</a> its services in China in June after U.S. export controls compelled the company to stop sales and support operations. It also&nbsp;paused its financial forecasts for both the third quarter and the fiscal year 2025.&nbsp;The approval arrives just weeks after President Donald Trump’s administration lifted restrictions on exports of critical semiconductor design tools to China.The ban, introduced in May, had impacted not only Chinese customers but also employees of foreign firms operating within China. Its lifting paved the way for the long-pending deal to resume progress, stated a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.scmp.com/tech/big-tech/article/3318140/tech-war-china-approves-synopsys-acquisition-ansys-after-us-lifts-eda-ban?module=perpetual_scroll_0&amp;pgtype=article">report</a> from SCMP.&nbsp;China's approval was granted under a set of obligations. The merged company is expected to provide Chinese customers with continued, unbiased access to electronic design automation tools.&nbsp;Additionally, the firms must honor all existing agreements, renew interoperability partnerships upon request, and preserve their current contractual commitments in the Chinese market.The deal is expected to bolster Synopsys’ position against rival Cadence, broadening its product suite and deepening its foothold in the EDA sector.&nbsp;On Stocktwits, retail sentiment toward Synopsys shifted to ‘neutral’ from ‘bearish’&nbsp; territory the previous day amid ‘low’ message volume levels.<figure class="image"><img style="aspect-ratio:807/104;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_7_27_58_AM_png_9595235e95.webp" alt="SNPS’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on July 14, 2025 | Source: Stocktwits" width="807" height="104"><figcaption>SNPS’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>Synopsys stock has gained over 15% year-to-date and has lost over 9% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-reportedly-strikes-2.4-b-licensing-deal-with-with-windsurf/ch8BFF2R5Vb">Alphabet Reportedly Strikes $2.4B Licensing Deal With Windsurf, Snags Founders And AI Researchers After OpenAI's Failed Bid</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Synopsys logo is seen displayed on a smartphone with the flag of China in the background. 

Synopsys-Ansys’ $35B Deal Reportedly Gets China’s Conditional Approval Days Before Closure Deadline

China’s approval removes the final global barrier for the deal, with conditions ensuring continued design tool access for Chinese customers and partners.

Equity

China approves Synopsys’ $35 bln Ansys acquisition

Investing.com-- China’s market regulator has provided conditional approval to Synopsys (NASDAQ:SNPS) for its $35 billion acquisition of Ansys (NASDAQ:ANSS), clearing a key regulatory hurdle for the U.S. chip-design software giant

ANSS Simulation Solutions Used by Wingcopter to Boost  Drone Designs

ANSS, Turbotech Team Up to Fuel a Hydrogen-Powered Future in Aviation

ANSYS, Inc. engages in the development and marketing of engineering simulation software and services. The firm's solutions include automotive, aerospace and defense, construction, energy, materials and chemical processing, autonomous engineering, and electrification. The company was founded by John A. Swanson in 1970 and is headquartered in Canonsburg, PA.

ANSS
Ansys Inc. - Registered Shares

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANSS News

ANSSAnsys Inc. - Registered Shares